

Appl. No. 10/016,850


Reply to Office Action of October 13, 2004

Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A topical ophthalmic composition comprising a carrier and a pharmaceutical conjugate comprising an ophthalmically useful therapeutic component and covalently coupled to an efficacy enhancing component effective in delivering the conjugate to a posterior portion of an eye of an individual when the composition is topically administered to the eye, the efficacy enhancing component has having the formula A:



wherein X is



R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are independently an H, a C₁-C₁₀ hydrocarbon, or a linker.

Appl. No. 10/016,850
Reply to Office Action of October 18, 2004

2. (Currently amended) A ~~pharmaceutical conjugate composition~~ of claim 1 wherein the therapeutic component and the efficacy enhancing component are directly joined by a covalent bond, and the carrier comprises a liquid.

3. (Currently amended) A ~~pharmaceutical conjugate composition~~ of claim 1 wherein the therapeutic component and the efficacy enhancing component are joined by a linker.


4. (Currently amended) A ~~pharmaceutical conjugate composition~~ of claim 1 wherein R1 and R2 are Hs, and R3 is a linker.

5. (Currently amended) A ~~pharmaceutical conjugate composition~~ of claim 1 wherein the efficacy enhancing component is a memantine.


6. (Currently amended) A ~~pharmaceutical conjugate composition~~ of claim 1 wherein the linker is selected from the group consisting of:

Appl. No. 10/016,850


Reply to Office Action of October 18, 2004




Linker B




Linker C




Linker D



Linker E



Linker F



Linker G



Linker H

Appl. No. 10/016,850

Reply to Office Action of October 18, 2004

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to 10, and n = 0 to 10.

7. (Withdrawn) A pharmaceutical conjugate of claim 1 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, tyrosine kinase inhibitors and neuroprotectants.

8. (Currently amended) A pharmaceutical conjugate composition of claim 1 wherein the therapeutic component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, ~~derivatives thereof~~ and mixtures thereof.

9. (Currently amended) A pharmaceutical conjugate composition of claim 1 wherein the efficacy enhancing component comprises a memantine, and the conjugate further comprises a linker joining the therapeutic component and the memantine.

10. (Withdrawn) A pharmaceutical conjugate of claim 1 wherein the therapeutic component comprises a timolol and the efficacy enhancing component comprises a memantine, and the conjugate further comprises a linker joining the timolol and the memantine.

Appl. No. 10/016,850

Reply to Office Action of October 13, 2004

11. (Currently amended) A ~~pharmaceutical conjugate~~ composition of claim 3 further comprising a memantine, and a linker joining the therapeutic component and the memantine.

12. (Currently amended) A ~~pharmaceutical conjugate~~ composition of claim 1 wherein the therapeutic component and the efficacy enhancing component disassociate under physiological conditions.

13. (Cancelled)


14. (Currently amended) A ~~pharmaceutical conjugate~~ composition of claim 1 wherein the conjugate has an aqueous solubility, a partition coefficient and/or an affinity for melanin that is greater relative to a compound comprising the same therapeutic component which is not joined to an efficacy enhancing component.

15. (Currently amended) A ~~pharmaceutical conjugate~~ composition of claim 1 ~~being~~ wherein the conjugate is a salt.


Appl. No. 10/016,850

Reply to Office Action of October 18, 2004

16. (Currently amended) A topical ophthalmic composition comprising a carrier and a pharmaceutical conjugate comprising an ophthalmically useful therapeutic component and covalently coupled to an efficacy enhancing component effective in delivering the conjugate to a posterior portion of an eye of an individual when the composition is topically administered to the eye, the efficacy enhancing component ~~has~~ having the formula A:




wherein X is




R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker; the linker is selected from the group consisting of:

Appl. No. 10/016,850


Reply to Office Action of October 18, 2004




Linker B




Linker C




Linker D



Linker E



Linker F



Linker G



Linker H

Appl. No. 10/016,850
Reply to Office Action of October 18, 2004

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to 10, and n
= 0 to 10.

17-23. (Cancelled)